Osteoarthritis and Cartilage



Brief report

An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid



M. Beekhuizen †^a, L.M. Gierman ‡§^a, W.E. van Spil ||, G.J.V.M. Van Osch ¶#, T.W.J. Huizinga §, D.B.F. Saris †††, L.B. Creemers †, A.-M. Zuurmond ‡*

† Department of Orthopaedics, University Medical Center Utrecht, Utrecht, The Netherlands

‡ TNO, Leiden, The Netherlands

§ Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

|| Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

¶ Department of Orthopaedics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

Department of Otorhinolaryngology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands

†† MIRA institute Tissue Reconstruction, University of Twente, Enschede, The Netherlands

ARTICLE INFO

Article history: Received 11 November 2012 Accepted 9 April 2013

Keywords: Synovial fluid Cytokines Chemokines Growth factors

SUMMARY

Objective: Soluble mediators in synovial fluid (SF) are acknowledged as key players in the pathophysiology of osteoarthritis (OA). However, a wide-spectrum screening of such mediators in SF is currently lacking. In this study, the levels of 47 mediators in the SF of control donors and osteoarthritic (OA) patients were compared.

Materials & Methods: SF was collected from control donors (n = 16) and end-stage knee OA patients (n = 18) and analysed for 47 cytokines, chemokines and growth factors using several multiplex enzyme-linked immunosorbent assays (ELISAs). A Mann–Whitney *U* test was used to determine differences between OA and control controls. A principal component analysis (PCA) was performed to cluster the 47 mediators. *Results*: The majority of the mediators could be detected in both control and OA SF. Interleukin (IL)-6, interferon inducible protein (IP)-10, macrophage derived chemokine (MDC), platelet derived growth factor (PDGF)-AA and regulated on activation normal T cell expressed and secreted (RANTES) levels were found to be higher in OA compared to control SF (P < 0.001). Leptin, IL-13, macrophage inflammatory protein (MIP)-1 β , soluble CD40 (sCD40L) levels were higher and eotaxin and granulocyte colony-stimulating factor (G-CSF) levels were lower in OA SF than in control SF, albeit borderline significant (P < 0.05). The PCA enabled identification of six clusters of mediators, which explained 76% of the variance.

Conclusions: The current study provides the first extensive profile of cytokines, chemokines and growth factors present in control and OA SF. Increased levels of mediators such as MDC and IL-6 imply involvement of inflammatory processes and might be associated with the influx of inflammatory cells in OA synovial tissue. Moreover, the performed cluster analysis indicated multiple clusters, which could indicate different pathophysiological pathways in the joint.

© 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Summary

Soluble mediators, e.g., cytokines, chemokines and growth factors, are acknowledged as key players in the pathophysiology of osteoarthritis (OA)^{1,2}. However, a wide-spectrum screening of such mediators in the joint environment is currently lacking. In this study, synovial fluid (SF) was collected from control donors and

^a Both authors contributed equally.

end-stage knee OA patients and analysed for 47 cytokines, chemokines and growth factors using several multiplex ELISAs. In addition, a principal component analysis (PCA) was performed to cluster the measured mediators. Interleukin (IL)-6, interferon inducible protein (IP)-10, macrophage derived chemokine (MDC), platelet derived growth factor (PDGF)-AA and regulated on activation normal T cell expressed and secreted (RANTES) levels were found to be higher in OA compared to control SF (P < 0.001). Leptin, IL-13, macrophage inflammatory protein (MIP)-1 β , soluble CD40 (sCD40L) levels were higher and eotaxin and granulocyte colonystimulating factor (G-CSF) levels were lower in OA SF than in control SF, albeit at borderline significance (P < 0.05). Increased levels of inflammatory mediators and chemokines, such as MDC

^{*} Address correspondence and reprint request to: A.-M. Zuurmond, TNO, Zernikedreef 9, P.O. Box 2215, 2301 CE Leiden, The Netherlands. Tel: 31-88-8660603; Fax: 31-88-8660603.

E-mail address: Anne-Marie.Zuurmond@tno.nl (A.-M. Zuurmond).

^{1063-4584/\$ –} see front matter © 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.joca.2013.04.002

and IL-6, imply involvement of inflammatory processes in OA and might be associated with the influx of inflammatory cells in OA synovial tissue. Additionally, the PCA enabled identification of six different clusters, which explained 76% of the variance, and in this way could indicate different pathophysiological pathways in the joint. This dataset is valuable as a reference for future experiments to study pathophysiological pathways, and useful in more extensive profiling studies for OA.

Brief report

A control group of knee SF samples (n = 16) were collected from post mortem donors within 24 h after death. Control donors had no history of OA, other joint pathology and possessed macroscopic healthy cartilage. OA SF samples (n = 18) were collected during total knee arthroplasty. All OA patients were diagnosed according to the American College of Rheumatology (ACR) criteria for OA³. Exclusion criteria were rheumatoid arthritis (RA) or infection. SF samples were centrifuged at 3,000 rpm for 3 min to spin down any cells or debris. The supernatant was stored at -80°C until further analysis. The control SF samples were stored for 1-10 years and OA SF samples were stored for 1–3 years. None of the samples had ever been thawed before. Collection of the SF was done according to the Medical Ethical regulations of the University Medical Centre Utrecht and according to the guideline 'good use of redundant tissue for clinical research' constructed by the Dutch Federation of Medical Research Societies on collection of redundant tissue for

research. As according to these guidelines, no information about the patients' characteristics could be obtained. Gender and age information was available for limited donors. Control donors had an average age of 39.6 ± 9.3 and consisted of 55% female. OA donors had an average age of 69.9 ± 7.9 and consisted of 64% female. Due to the limited availability these data could not be linked to any of the outcomes.

Two hundred microlitre of each of the OA SF samples was pretreated with 20 μ l of hyaluronidase (Sigma, St. Louis, MO, USA; 10 mg/ml) for 15 min at 37°C. Samples were spun down in a Xcolumn (Corning, Amsterdam, Netherlands; Costar 8169). Finally, 150 μ l of the SF sample was dissolved in 300 μ l high performance ELISA (HPE)-0.1375% Tween (Sanquin, Amsterdam, Netherlands). The pre-treated SF samples were used for all Multiplex ELISA assays mentioned below.

To determine a wide panel of soluble mediators the commercially available human inflammation 42-multiplex and the human adipokine 13-multiplex (Millipore, Bellirica, MA, USA) were used according to the manufacturer's protocol. Additionally, 12 different soluble mediators were measured with the Bio-Plex suspension system (Bio-Rad laboratories, Hercules CA, USA) as previously described⁴. The levels of cytokines in the SF samples were expressed as pg/ml. All samples were measured in the same plate and in duplo. Levels below the lower limit of quantification (LLOQ) were indicated as the value of the lowest point on the calibration curve divided by 2. The measured mediators are listed in Table I. Data are expressed as median \pm interquartile range (IqR) as the

Table I

Overview of the measured mediator concentration (pg/ml) in control and osteoarthritic (OA) SF. Data are indicated as median \pm lqR. The coefficient of variation (CV) in percentage and lower limit of quantification (LLOQ) with the number of samples are given. Data are subjected to non-parametric statistical analysis Mann–Whitney *U*; **P* < 0.05 and #*P* < 0.001. GM-CSF, IL-12(p70), IL-13, IL-2, IL-4, IL-5, IL-9, TNF α , TNF β , VEGF and NGF could not be detected

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					-				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Healthy SF	CV (%)	<lloq< th=""><th>OA SF</th><th>CV (%)</th><th><lloq< th=""><th>Detection</th><th>Mann-Whitney</th></lloq<></th></lloq<>	OA SF	CV (%)	<lloq< th=""><th>Detection</th><th>Mann-Whitney</th></lloq<>	Detection	Mann-Whitney
EGF4.8 ± 13.1102.3114.8 ± 0189.3145.30.65Eotaxin14.6 ± 39.696.060 ± 0236.71512.1*0.02Fibroblast growth37.2 ± 70.4137.5221.6 ± 231.4134.1416.00.67Fibroblast growth35.9 ± 119.759.00103.5 ± 76.453.106.10.23Fractalkine0 ± 0387.7140 ± 1966.5127.60.14C-CSF34.8 ± 151105.9116.9 ± 1566.903.9*0.03Growth regulated59.2 ± 79.574.4084.2 ± 9681.6011.40.38oncogene (GRO)716.4 ± 46.889.3727.20.09IFN γ 40.7 ± 12.923.30028.0 ± 21.0136.7422.140.1IL-1203.4 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-12048.1.7012.8 ± 5.731.200.660.32IL-140 ± 1.8217.890 ± 0.9153.4121.50.74IL-159.9 ± 6.037.1012.8 ± 5.731.200.660.32IL-140 ± 1.8215.680 ± 0179.3169.80.18IL-150 ± 00.0164.8 ± 0179.3169.80.18<		(median $\pm IqR$)		or 0 (<i>n</i>)	(median $\pm IqR$)		or 0 (<i>n</i>)	limit	U(P-value)
Eotaxin14.6 \pm 39.696.060 \pm 0236.71512.1'0.02Fibroblast growth37.2 \pm 70.437.020.6 \pm 231.4134.1416.00.67factor (FCF)-2Firatalkine0 \pm 0387.7140 \pm 19168.5127.60.140.23Growth regulated0 \pm 2.4 \pm 7.574.4084.2 \pm 9681.603.9'0.03Growth regulated59.2 \pm 79.574.4084.2 \pm 9681.6011.40.38oncogene (GRO)0.9IFN γ 40.7 \pm 12.923.30028.0 \pm 21.0136.7422.140.1IL-1203.3 \pm 6.3127.662.1 \pm 2.7103.730.3*0.04IL-1203.4 \pm 17012.8 \pm 5.731.200.600.32IL-120.4 \pm 3.1012.8 \pm 5.731.200.610.32IL-130.4 \pm 17.50.74134.8 \pm 1013.71012.40.30IL-140.4 \pm 17.50.594.8 \pm 11.913.71012.40.30IL-150.9 \pm 6.037.1012.8 \pm 5.731.200.60.32IL-1604.8 \pm 17012.8 \pm 5.731.200.6	EGF	4.8 ± 13.1	102.3	11	4.8 ± 0	189.3	14	5.3	0.65
Fibroblast growth factor (FCF)-237.2 ± 70.4137.5221.6 ± 231.4134.1416.00.67factor (FCF)-2135.9 ± 119.759.00103.5 ± 76.453.106.10.23Fractalkine0 ± 0387.7140 ± 19168.5127.60.14G-CSF34.8 ± 151105.9116.9 ± 1566.903.9*0.03Growth regulated59.2 ± 79.574.4084.2 ± 9681.6011.40.38oncogene (GRO)16.4 ± 46.889.3727.20.09IFN γ40.7 ± 12.923.30028.0 ± 21.0136.7422.140.1IL-103.3 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-12 (p40)4.8 ± 1.760.594.8 ± 11.9137.71012.40.30IL-159.9 ± 6.037.1012.8 ± 5.731.200.60.32IL-140 ± 1.8217.890 ± 4.9153.4121.50.74IL-159.9 ± 6.037.1012.8 ± 5.731.200.60.32IL-160 ± 00.0164.8 ± 0179.3169.80.18IL-170 ± 00.115.8 ± 224.6120.330.4*0.001IL-180 ± 0030 ± 23.5170.900.30.24IL-18	Eotaxin	14.6 ± 39.6	96.0	6	0 ± 0	236.7	15	12.1	*0.02
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Fibroblast growth	$\textbf{37.2} \pm \textbf{70.4}$	137.5	2	21.6 ± 231.4	134.1	4	16.0	0.67
FIt-3 ligand135.9 ± 119.759.00103.5 ± 76.453.106.10.23Fractalkine0 ± 0387.7140 ± 19168.5127.60.14G-CSF34.8 ± 151105.9116.9 ± 1566.903.9'0.03Growth regulated59.2 ± 79.574.4084.2 ± 9681.6011.40.38oncogene (GRO)89.3727.20.09IFNq40.7 ± 12.923.30028.0 ± 21.0136.7422.140.1IL-103.3 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-12 (p40)48 ± 1.760.5948.8 ± 11.9137.71012.40.30IL-159.9 ± 6.037.1012.8 ± 5.731.200.60.32IL-160 ± 1.8217.890 ± 0.9153.4121.50.74IL-17a0 ± 1.6205.41148 ± 11.9288.6140.70.61IL-30 ± 00.01648 ± 0179.3169.80.18IL-648 ± 0196.913135.8 ± 224.6120.330.4*0.001IL-648 ± 0196.913135.8 ± 224.6120.330.4*0.001IL-648 ± 0196.913135.8 ± 224.6120.330.4*0.001IL-648 ±	factor (FGF)-2								
Fractalkine 0 ± 0 387.7 14 0 ± 19 168.5 12 7.6 0.14 G-CSF 34.8 ± 151 105.9 1 16.9 ± 15 66.9 0 3.9 $^{\circ}0.03$ Growth regulated 59.2 ± 79.5 74.4 0 84.2 ± 96 81.6 0 11.4 0.38 $oncogene (GRO)$ 7.2 ± 10.5 67.4 7 16.4 ± 46.8 89.3 7 27.2 0.09 IFN γ 40.7 ± 12.9 23.30 0 28.0 ± 21.0 136.74 2 2.14 0.1 IL-10 3.3 ± 6.3 127.6 6 2.1 ± 2.7 103.7 3 0.3 $^{\circ}0.04$ IL-12 (p40) 4.8 ± 1.7 60.5 9 4.8 ± 11.9 137.7 10 12.4 0.30 IL-15 9.9 ± 6.0 37.1 0 12.8 ± 5.7 31.2 0 0.6 0.32 IL-16 0 ± 1.8 217.8 9 0 ± 4.9 153.4 12 1.5 0.74 IL-17a 0 ± 6.9 125.6 8 0 ± 0 28.4 14 0.7 0.61 IL-18 0 ± 0 0.0 16 4.8 ± 10 79.3 16 9.8 0.18 IL-18 0 ± 0 0.9 13 135.8 ± 224.6 120.3 3 0.4 $^{\circ}0.001$ IL-6 4.8 ± 0 196.9 13 135.8 ± 224.6 120.3 3 0.4 $^{\circ}0.001$ IL-6 4.8 ± 0 196.9 13	Flt-3 ligand	135.9 ± 119.7	59.0	0	103.5 ± 76.4	53.1	0	6.1	0.23
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Fractalkine	0 ± 0	387.7	14	0 ± 19	168.5	12	7.6	0.14
Growth regulated oncogene (GR0)59.2 ± 79.574.4084.2 ± 9681.6011.40.38IFNα27.2 ± 10.567.4716.4 ± 46.889.3727.20.09IFNα23.3 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-103.3 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-12 (p40)48 ± 1.760.594.8 ± 11.9137.71012.40.30IL-159.9 ± 6.037.1012.8 ± 5.731.200.60.32IL-17α0 ± 1.8217.890 ± 4.9153.4121.50.74IL-180 ± 1.5205.4114.8 ± 11.9298.6140.70.61IL-30 ± 00.0164.8 ± 0179.3169.80.011.8IL-64.8 ± 0179.3169.80.011.4*0.0011.4IL-70.21 ± 280.8107.6071.4 ± 597.193.101.3*0.001IL-190.21 ± 280.8107.6071.4 ± 597.193.101.3*0.001IL-752.2 ± 38.4123.5104.8 ± 645.547.801.20.58MCP-34.8 ± 36123.5104.8 ± 645.514.85.20.83MDC52.2 ± 38.413.512.5145.20.83MDC52.2 ± 38.4 <t< td=""><td>G-CSF</td><td>34.8 ± 151</td><td>105.9</td><td>1</td><td>16.9 ± 15</td><td>66.9</td><td>0</td><td>3.9</td><td>*0.03</td></t<>	G-CSF	34.8 ± 151	105.9	1	16.9 ± 15	66.9	0	3.9	*0.03
oncogene (GRO)IFNα27.2 ± 10.567.4716.4 ± 46.889.3727.20.09IFNγ40.7 ± 12.923.30028.0 ± 21.0136.7422.140.1IL-103.3 ± 6.3127.662.1 ± 2.7103.730.3*0.04IL-12 (p40)4.8 ± 1.760.594.8 ± 1.9137.71012.40.30IL-159.9 ± 6.037.1012.8 ± 5.731.200.60.32IL-1α0 ± 1.8217.890 ± 4.9153.4121.50.74IL-1β0 ± 1.5205.4114.8 ± 11.9298.6140.70.61IL-30 ± 00.0164.8 ± 0179.3169.80.18IL-64.8 ± 0199.913135.8 ± 224.6120.330.4*0.001IL-816.2 ± 43.592.2030 ± 23.5170.900.30.24IP-10302.1 ± 280.8107.60710.4 ± 597.193.101.3*0.001MCP-1542.4 ± 839.2102.10824.8 ± 645.547.801.20.58MDC52.2 ± 38.443.90189.5 ± 119.841.802.4*0.001MDC52.2 ± 38.443.90189.5 ± 119.841.802.4*0.001MDC52.2 ± 38.443.90189.5 ± 119.841.802.4<	Growth regulated	59.2 ± 79.5	74.4	0	84.2 ± 96	81.6	0	11.4	0.38
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	oncogene (GRO)								
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IFNa2	7.2 ± 10.5	67.4	7	16.4 ± 46.8	89.3	7	27.2	0.09
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IFNγ	40.7 ± 12.9	23.30	0	28.0 ± 21.0	136.74	2	2.14	0.1
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IL-10	3.3 ± 6.3	127.6	6	2.1 ± 2.7	103.7	3	0.3	*0.04
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IL-12 (p40)	4.8 ± 1.7	60.5	9	$\textbf{4.8} \pm \textbf{11.9}$	137.7	10	12.4	0.30
	IL-15	9.9 ± 6.0	37.1	0	12.8 ± 5.7	31.2	0	0.6	0.32
	IL-1a	0 ± 1.8	217.8	9	0 ± 4.9	153.4	12	1.5	0.74
	IL-1ra	0 ± 6.9	125.6	8	0 ± 0	288.4	14	2.3	0.14
$ IL-3 \qquad 0 \pm 0 \qquad 0.0 \qquad 16 \qquad 4.8 \pm 0 \qquad 179.3 \qquad 16 \qquad 9.8 \qquad 0.18 \\ IL-6 \qquad 4.8 \pm 0 \qquad 196.9 \qquad 13 \qquad 135.8 \pm 224.6 \qquad 120.3 \qquad 3 \qquad 0.4 \qquad {}^{*}0.001 \\ IL-8 \qquad 16.2 \pm 43.5 \qquad 92.2 \qquad 0 \qquad 30 \pm 23.5 \qquad 170.9 \qquad 0 \qquad 0.3 \qquad 0.24 \\ IP-10 \qquad 302.1 \pm 280.8 \qquad 107.6 \qquad 0 \qquad 710.4 \pm 597.1 \qquad 93.1 \qquad 0 \qquad 1.3 \qquad {}^{*}0.001 \\ MCP-1 \qquad 542.4 \pm 839.2 \qquad 102.1 \qquad 0 \qquad 824.8 \pm 645.5 \qquad 47.8 \qquad 0 \qquad 1.2 \qquad 0.58 \\ MCP-3 \qquad 4.8 \pm 36 \qquad 123.5 \qquad 10 \qquad 4.8 \pm 5 \qquad 215.5 \qquad 14 \qquad 5.2 \qquad 0.83 \\ MDC \qquad 52.2 \pm 38.4 \qquad 43.9 \qquad 0 \qquad 189.5 \pm 119.8 \qquad 41.8 \qquad 0 \qquad 2.4 \qquad {}^{*}0.001 \\ MIP-1\alpha \qquad 4.8 \pm 0 \qquad 26.7 \qquad 16 \qquad 4.8 \pm 0 \qquad 172.7 \qquad 15 \qquad 6.6 \qquad 0.06 \\ MIP-1\beta \qquad 9.6 \pm 24.0 \qquad 83.7 \qquad 5 \qquad 21.8 \pm 23.5 \qquad 127.6 \qquad 3 \qquad 3.2 \qquad {}^{*}0.04 \\ $	IL-1β	0 ± 1.5	205.4	11	4.8 ± 11.9	298.6	14	0.7	0.61
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IL-3	0 ± 0	0.0	16	4.8 ± 0	179.3	16	9.8	0.18
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IL-6	4.8 ± 0	196.9	13	135.8 ± 224.6	120.3	3	0.4	[#] 0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IL-8	16.2 ± 43.5	92.2	0	30 ± 23.5	170.9	0	0.3	0.24
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	IP-10	$\textbf{302.1} \pm \textbf{280.8}$	107.6	0	710.4 ± 597.1	93.1	0	1.3	[#] 0.001
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MCP-1	542.4 ± 839.2	102.1	0	824.8 ± 645.5	47.8	0	1.2	0.58
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MCP-3	4.8 ± 36	123.5	10	4.8 ± 5	215.5	14	5.2	0.83
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	MDC	52.2 ± 38.4	43.9	0	189.5 ± 119.8	41.8	0	2.4	[#] 0.001
$MIP-1\beta \qquad 9.6 \pm 24.0 \qquad 83.7 \qquad 5 \qquad 21.8 \pm 23.5 \qquad 127.6 \qquad 3 \qquad 3.2 \qquad {}^{*}0.04$	MIP-1a	4.8 ± 0	26.7	16	4.8 ± 0	172.7	15	6.6	0.06
	MIP-1β	9.6 ± 24.0	83.7	5	21.8 ± 23.5	127.6	3	3.2	*0.04
PDGF-AA 0 ± 2.1 201.3 11 72.6 ± 116.9 72.8 0 0.3 [#] 0.001	PDGF-AA	0 ± 2.1	201.3	11	$\textbf{72.6} \pm \textbf{116.9}$	72.8	0	0.3	[#] 0.001
PDGF-AB/BB 43.2 ± 42.9 93.6 1 34.2 ± 69.7 137.8 0 12.2 0.44	PDGF-AB/BB	43.2 ± 42.9	93.6	1	34.2 ± 69.7	137.8	0	12.2	0.44
RANTES 15.6 ± 28.1 152.7 0 408.2 ± 910.9 114.3 0 1.6 [#] 0.001	RANTES	15.6 ± 28.1	152.7	0	408.2 ± 910.9	114.3	0	1.6	[#] 0.001
sCD40L 0 ± 0 230.9 13 5.9 ± 45.1 144.6 7 5.2 *0.005	sCD40L	0 ± 0	230.9	13	5.9 ± 45.1	144.6	7	5.2	*0.005
slL-2ra 37.5 ± 76.8 90.8 1 63.0 ± 72.5 65.9 0 7.5 0.11	sIL-2ra	$\textbf{37.5} \pm \textbf{76.8}$	90.8	1	63.0 ± 72.5	65.9	0	7.5	0.11
TGF α 0 ± 0.6 201.2 9 0 ± 0 401.5 17 1.4 0.4	TGFa	0 ± 0.6	201.2	9	0 ± 0	401.5	17	1.4	0.4
HGF 2554.4 ± 3505.7 80.2 0 2303 ± 1695.2 38.12 0 1.6 0.32	HGF	2554.4 ± 3505.7	80.2	0	2303 ± 1695.2	38.12	0	1.6	0.32
Leptin 82.2 ± 1565.3 133.21 4 1637.5 ± 2414.1 125.33 0 27.4 *0.01	Leptin	82.2 ± 1565.3	133.21	4	1637.5 ± 2414.1	125.33	0	27.4	*0.01
Resistin 2713.4 ± 1854.6 87.25 0 3824.8 ± 3550.7 72.71 04.50.12	Resistin	2713.4 ± 1854.6	87.25	0	3824.8 ± 3550.7	72.71	0	4.5	0.12
Adiponectin >250,000 na na >250,000 na na 80.3 na	Adiponectin	>250,000	na	na	>250,000	na	na	80.3	na
OSM 0 ± 0 447.83 16 0 ± 0 307.79 12 1.59 0.09	OSM	0 ± 0	447.83	16	0 ± 0	307.79	12	1.59	0.09

Download English Version:

https://daneshyari.com/en/article/6125464

Download Persian Version:

https://daneshyari.com/article/6125464

Daneshyari.com